

Dr.ssa Valentina Sangiorgio

Dipartimento di Anatomia Patologica, FPO-IRCCS Istituto di Candiolo. Candiolo, TO Università degli Studi di Milano, Bicocca



## Linfoma di Hodgkin a Predominanza Linfocitaria: Nuova Classificazione WHO vs ICC 2022



### No Disclosures



## **NLPHL:** Introduction

- Around 5% of all HLs
- M:F = 3:1
- Median age at presentation: 30-40 yrs  $\bullet$
- Localized disease: 60-70% stage I-II
- Advanced stage: 30-40% stage III-IV (especially so called «variant patterns»)
- Transformation to B-NHL: ~5% (especially so called «variant patterns»)





## NLPHL: General histopathologic aspects

- B cell neoplasm with paucity of large neoplastic cells: «lymphocyte predominant» (LP) cells or «pop corn» cells
- Abundance of background inflammatory cells
- Pattern of growth: predominantly nodular •
- $\bullet$




From first description (1947) included within HL: «Hodgkin Paragranuloma» ->> «Nodular Lymphocyte Predominant HL»



### ICC 2022: NLPHL renamed «Nodular Lymphocyte Predominant B-cell Lymphoma»

WHO 2022: NLPHL retains its name was not to interfere with ongoing trials. However, it may be more accurately called «Nodular Lymphocyte Predominant B-cell Lymphoma»









## I. Cell of Origin



## NLPHL and cHL Derive from Germinal Center B Cells

### NLPHL



The NEW ENGLAND JOURNAL of MEDICINE

### Origin of Nodular Lymphocyte-Predominant Hodgkin's Disease from a Clonal Expansion of **Highly Mutated Germinal-Center B Cells**

Authors: Theresa Marafioti, M.D., Michael Hummel, Ph.D., Ioannis Anagnostopoulos, M.D., Hans-Dieter Foss, M.D., Brunangelo Falini, M.D., Georges Delsol, M.D., Peter G. Isaacson, M.D., Stefano Pileri, M.D., and Harald Stein,

N Engl J Med. 1997 Aug 14;337(7):453-8.

## PNAS

### Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells

A Braeuninger<sup>1</sup>, R Küppers, J G Strickler, H H Wacker, K Rajewsky, M L Hansmann

Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9337-42.

# The young side of LYMPHOMA

### CHL



Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells.

H Kanzler, R Küppers, M L Hansmann, K Rajewsky


J Exp Med. 1996 Oct 1;184(4):1495-505.

## **S**blood


Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription

Theresa Marafioti, Michael Hummel, Hans-Dieter Foss, Helmut Laumen, Petra Korbjuhn, Ioannis Anagnostopoulos, Hetty Lammert, Gudrun Demel, Jan Theil, Thomas Wirth, and Harald Stein

Blood. 2000 Feb 15;95(4):1443-50.



## NLPHL and cHL Derive from Germinal Center B Cells






# The young side of LYMPHOMA

- PCR on DNA extracted from purified CD30+ cells (cHL) and CD20+ cells (NLPHL)
- Sequencing of  $V_H$  genes
- V<sub>H</sub> gene amplification products derived from HRS/ LP cells identical in each patient
- Evidence of somatic hypermutations •



## NLPHL and cHL Have Different Ig Protein Expression



Pescara, 11-12 ottobre 2024

### NLPHL

### Ig gene transcription/ translation effective = LPs show Ig expression at mRNA/ protein level

- Dependence from antigenic stimulation
- Intraclonal diversity in rearranged Ig genes

### cHL

# Ig gene transcription/ translation ineffective = HRS lack Ig expression at mRNA/ protein level

- Independence from antigenic stimulation
- Upregulation of anti-apoptotic pathways
  - No intraclonal diversity



### II. Histopathologic aspects




## NLPHL and cHL have distinct morphology and immunophenotype

cHL			
Neoplastic cell	Hodgkin/ Reed Sternberg (HRS)		
Phenotype	CD20-, CD79a-, PAX5+		
	CD30+, CD15+		
	Oct2-, BOB1-		
	PD-L1+		
EBV status	~20% EBV+ (Mixed Cellularity)		
Background	More heterogeneous		



# The young side of LYMPHOMA

### NLPHL



Lymphocyte-Predominant (LP)

### CD20+, CD79a+, PAX5+

CD30-, CD15-

Oct2+, BOB1+


PD-L1-

EBV negative

Lymphs/Histiocytes



## Variant histologic patterns in NLPHL




### Typical A/B Patterns

- Most common patterns in NLPHL  $\bullet$
- Nodular architecture with FDC meshworks •
- LP cells embedded in a B cell rich environment
- Fewer CD4/PD1 <sup>pos</sup> T rosetting around LP cells
- More common limited stage
- Rarer progression into aggressive B-NHL •



### Variant histologic patterns in NLPHL




### Variant C-F Patterns

- Rarer patterns in NLPHL ۲
- Variable reduction/ loss of nodular architecture •
- Progressive reduction of B lymphocytes
- LP cells embedded in a T cell rich environment •
- More common advanced stage •
- Higher propensity to progress in B-NHL  $\bullet$



### Variant histologic patterns in NLPHL



Pescara, 11-12 ottobre 2024

### Variant E Pattern

- Also known as «THRLBL-like NLPHL»
- Similar cell composition to THRLBL de novo
- «Distinction from THRLBL relies on at least one unequivocal nodule with features of NLPHL»







CME Article

### The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)

```
Sylvia Hartmann <sup>1,</sup> \stackrel{\circ}{\sim} \stackrel{\boxtimes}{\sim}, Dennis A. Eichenauer <sup>2, 3</sup>, Annette Plütschow <sup>2, 3</sup>, Anja Mottok <sup>4</sup>,
Roshanak Bob<sup>5</sup>, Karoline Koch<sup>6</sup>, Heinz-Wolfram Bernd<sup>7</sup>, Sergio Cogliatti<sup>8</sup>, Michael Hummel<sup>9</sup>,
Alfred C. Feller <sup>7</sup>, German Ott <sup>10</sup>, Peter Möller <sup>11</sup>, Andreas Rosenwald <sup>4</sup>, Harald Stein <sup>5</sup>,
Martin-Leo Hansmann<sup>1</sup>, Andreas Engert<sup>2, 3</sup>, Wolfram Klapper<sup>6</sup>
```




# The young side of LYMPHOMA

### Table 2. Clinical parameters of typical NLPHL patients compared with histopathologic NLPHL variants

	Typical NLPHL (pattern A/B), n = 308%	NLPHL variant pattern (non-A/B), n = 105%	Fisher exact test
Clinical stages III/IV or IIB with a large mediastinal mass and/or extranodal disease	14.6	29.5	<i>P</i> = .0012
International Prognostic Score (IPS) ≥3*	3.3	14.3	<i>P</i> = .0005
Male gender	72.4	79.0	n.s.
Stage IV	1.9	11.4	<i>P</i> = .0002
Age ≥45 y	38.6	29.5	n.s.
Albumin <4 g/dL	10.7	18.8	n.s.
Hemoglobin <10.5 g/dL	0.7	4.8	<i>P</i> = .0136
Leukocytes >15 000/mm <sup>3</sup>	0.3	1.0	n.s.
Lymphocytes <600/mm <sup>3</sup>	0.7	1.0	n.s.
Splenic involvement	6.7	3.2	n.s.
Disease progression or relapse in the first 5 years after study enrollment in the GHSG	6.5	18.1	P = .0009



## Pattern of Transformation/ Evolution in NLPHL




## III. Gene Expression Profiling



### Origin and pathogenesis of nodular lymphocytepredominant Hodgkin lymphoma as revealed by global gene expression analysis J Exp Med (2008) 205 (10): 2251-2268.

Verena Brune, Enrico Tiacci, Ines Pfeil, Claudia Döring, Susan Eckerle, Carel J.M. van Noesel, Wolfram Klapper, Brunangelo Falini, Anja von Heydebreck, Dirk Metzler, Andreas Bräuninger, Martin-Leo Hansmann, Ralf Küppers



### GEP of tumor cells in Germinal Center Derived B-NHL


PC1

Pescara, 11-12 ottobre 2024

### Nodular Lymphocyte Predominant Hodgkin Lymphoma and T Cell/Histiocyte Rich Large B Cell Lymphoma -Endpoints of a Spectrum of One Disease? PLoS One. 2013 Nov 11;8(11):e78812.


Sylvia Hartmann<sup>1</sup>\*, Claudia Döring<sup>1</sup>, Christina Jakobus<sup>1</sup>, Benjamin Rengstl<sup>1</sup>, Sebastian Newrzela<sup>1</sup>, Thomas Tousseyn<sup>2</sup>, Xavier Sagaert<sup>2</sup>, Maurilio Ponzoni<sup>3</sup>, Fabio Facchetti<sup>4</sup>, Chris de Wolf-Peeters<sup>2</sup>, Christian Steidl<sup>5</sup>, Randy Gascoyne<sup>5</sup>, Ralf Küppers<sup>6</sup>, Martin-Leo Hansmann<sup>1</sup>

GEP of tumor cells in NLPHL, THRLBCL-like NLPHL and THRLBCL





### Quantification of the microenvironment in typical NLPHL (patterns A and C), THRLBCL-like NLPHL (pattern E) and THRLBCL




Pescara, 11-12 ottobre 2024

# The young side of LYMPHOMA

### Nodular Lymphocyte Predominant Hodgkin Lymphoma and T Cell/Histiocyte Rich Large B Cell Lymphoma -Endpoints of a Spectrum of One Disease? PLoS One. 2013 Nov 11;8(11):e78812.

Sylvia Hartmann<sup>1</sup>\*, Claudia Döring<sup>1</sup>, Christina Jakobus<sup>1</sup>, Benjamin Rengstl<sup>1</sup>, Sebastian Newrzela<sup>1</sup>, Thomas Tousseyn<sup>2</sup>, Xavier Sagaert<sup>2</sup>, Maurilio Ponzoni<sup>3</sup>, Fabio Facchetti<sup>4</sup>, Chris de Wolf-Peeters<sup>2</sup>, Christian Steidl<sup>5</sup>, Randy Gascoyne<sup>5</sup>, Ralf Küppers<sup>6</sup>, Martin-Leo Hansmann<sup>1</sup>



## NLPHL- Conclusions

- I. CELL OF ORIGIN:
- Germinal Center Derived B Cell Neoplasm with a retained dependence from antigen stimulation
- II. HISTOPATHOLOGY:
- Distinct entity with defined histopathologic features compared to cHL and other B-NHL
- Identification of histopathologic patterns has relevant prognostic implications
- «Dinamic entity» with progression associated mostly with a modification in tumor microenvironment

III. GENE EXPRESSION PROFILING:

• GEP of LP cells similar to HRS and other B-NHL, especially THRLBL



### The Conservatives

### The Italians' Approach





## Classification of NLPHL... a matter of point of view



The Progressives

### References

Brune V, Tiacci E, Pfeil I, et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med. 2008;205(10):2251-2268.

Hartmann S, Eichenauer DA, Plütschow A, et al. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood. 2013;122(26):4246-4292.

Hartmann S, Eichenauer DA. Nodular lymphocyte predominant Hodgkin lymphoma: pathology, clinical course and relation to T-cell/histiocyte rich large B-cell lymphoma. Pathology. 2020;52(1):142-153.

Kanzler H, Küppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med. 1996;184(4):1495-1505.

Stein H, Marafioti T, Foss HD, et al. Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood. 2001;97(2):496-501

Marafioti T, Hummel M, Anagnostopoulos I, et al. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med. 1997;337(7):453-458. Marafioti T, Hummel M, Foss HD, et al. Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but

defective immunoglobulin transcription. Blood. 2000;95(4):1443-1450.

Panayi C, Akarca AU, Ramsay AD, et al. Microenvironmental immune cell alterations across the spectrum of nodular lymphocyte predominant Hodgkin lymphoma and T-cell/histiocyte-rich large B-cell lymphoma. Front Oncol. 2023;13:1267604.



# The young side of LYMPHOMA



